Adverse reactions and safety profile of the mRNA COVID-19 vaccines among Asian military personnel
Joshua-T-C TAN; Clive TAN; Jeremy TEOH; M-T WAHAB; Guan-Zhong TAN; Reon-Yew-Zhou CHIN; Anne LEE; Adeliza MUTALIB; Poh-Lian LIM.
Annals of the Academy of Medicine, Singapore
; : 827-837, 2021.
Artículo
en Inglés
| WPRIM | ID: wpr-921085
INTRODUCTION@#The use of novel mRNA platforms for COVID-19 vaccines raised concern about vaccine safety, especially in Asian populations that made up less than 10% of study populations in the pivotal vaccine trials used for emergency use authorisation. Vaccine safety issues also remain a concern in assessing the clinical risks and benefits of vaccine boosters, particularly in specific age groups or segments of the population. This study describes a vaccination exercise involving Asian military personnel, and the adverse reactions and safety events observed.@*METHODS@#Minor adverse reactions, hospitalisations and adverse events of special interest were monitored as part of the organisation's protocol for safety monitoring of COVID-19 vaccinations. All vaccine recipients were invited to complete an online adverse reaction questionnaire. Medical consults at the military's primary healthcare facilities were monitored for vaccine-related presentations. All hospitalisations involving vaccine recipients were analysed. Adverse reaction rates between doses, vaccines and age groups were compared.@*RESULTS@#A total of 127,081 mRNA vaccine doses were administered to 64,661 individuals up to 24 July 2021. Common minor adverse reactions included fever/chills, body aches and injection site pain. These were more common after dose 2. Younger individuals experienced minor adverse reactions more frequently. Rare cases of anaphylaxis, Bell's palsy and myocarditis/pericarditis were observed. No deaths occurred.@*CONCLUSION@#Minor adverse reactions were less common than reported in other studies, and rates of anaphylaxis, Bell's palsy and myocarditis/pericarditis were comparable. Our study supports the favourable safety profile of mRNA COVID-19 vaccines, which may help guide decisions about booster doses if required.
Biblioteca responsable:
WPRO
Texto completo
Documentos relacionados